It has been well established that the antihypertensive drug hydralazine (Sutton, 1986) , when injected into animals at high doses, can substantially decrease blood flow to a variety of transplanted tumours (Voorhees and Babbs, 1982; Chaplin and Acker, 1987; Horsman et al., 1989 Horsman et al., , 1992 Bhujwalla et al., 1990; Kalmus et al., 1990; Lin and Song, 1990; Fisker et al., 1991; Honess and Bleehen, 1992; Dewhirst et al., 1994) . This effect leads to changes in tumour oxygenation (Stratford et al., 1987; Horsman et al., 1989; Lin and Song, 1990; Fisker et al., 1991 ; Lemmon and Brown, 1991) and energy metabolism (Okunieff et al., 1988; Bhujwalla et al., 1990; Tozer et al., 1990; Bremner et al., 1991) , and as a result this drug will enhance the anti-tumour activity of a range of agents. These include hypoxic cell cytotoxins such as bioreductive drugs Bremner et al., 1990) and hyperthermia (Horsman et al., 1989; Kalmus et al., 1990) , as well as certain conventional chemotherapeutic agents such as melphalan (Stratford et al., 1987; Adams et al., 1989; Chaplin et al., 1989) and chlorambucil (Skarsgard et al., 1992) .
However, recent studies using 31P magnetic resonance spectroscopy (31P-MRS) reported that primary or spontaneous murine tumours were in general unresponsive to hydralazine (Field et al., 1991; Wood et al., 1992) . Moreover, when one of the unresponsive primary tumours was subcutaneously transplanted into the flanks of isogeneic mice it did respond to hydralazine (Field et al., 1991 
Materials and methods
Transplanted tumour A C3H mouse mammary carcinoma was used. Its derivation and maintenance have been described previously (Overgaard, 1980) . Experimental tumours were produced following sterile dissection of large flank tumours. Macroscopically viable tumour tissue was minced with a pair of scissors and 5-10 lL of this material injected subcutaneously on the backs of 10-14-week old male and female C3D2Fl/Bom (C3H/Tif female x DBA/2 male) mice. Measurements of tumour oxygenation were carried out when tumours had achieved volumes ranging from about 500 to 5000 mm3 (see Table I ), tumour size being determined by the formula DI x D2
x D3 x n/6 (where the D values represent three orthogonal diameters). This size range was selected to allow direct comparison with our spontaneous tumours.
Spontaneous tumours
The characteristics of the spontaneous mouse tumours are also listed in Table I . Tumours were used when they had reached about 500-5000 mm3 in size. These volumes were chosen because they were similar to the range of spontaneous tumour volumes used in previous 31P-MRS studies (Field et al., 1991) . Our spontaneous tumours were not deliberately produced for these experiments but arose at different sites in male and female C3D2Fl/Bom mice aged between 14 and 28 months that had previously undergone some form of radiation treatment at around 3 months of age in connection with other experiments. Two mice had received whole body irradiation with 6-8 Gy given in three daily fractions. 
PO2 measurements
Measurements of tumour P02 were made using a computerised fine-needle polarographic oxygen electrode probe (Eppendorf, Hamburg, Germany), the details of which have been described previously (Kallinowski et al., 1990) . The location of some of the spontaneous tumours required the use of an anaesthetic, thus for consistency p02 measurements in all the spontaneous and transplanted tumours were performed under anaesthesia. To achieve this mice were given a single injection with a mixture of hypnorm (fluanisonum 10mg ml' + fentanyl 0.2mg ml'), diazepam (5 mg ml-') and water in the ratio of 1:1:4. This mixture was injected intraperitoneally at 0.005 ml g-' mouse body weight. 
Results
Histological characterisation of the spontaneous tumours showed that half of them were adenocarcinomas ( Table I) . The remainder being a malignant lymphoma, a sarcoma, an anaplastic tumour and one tumour (mouse number 3) which histologically was actually found to consist of highly vascularised, yet necrotic tissue, with no malignant cells being seen. Seven of the tumours also had their DNA-index determined and of these, five were diploid (DNA index of 1.00), while the remaining two were either hypotetraploid (mouse number 2) or hypertetraploid (mouse number 4). The transplanted C3H mouse mammary carcinoma was found to be tetraploid with a DNA index of 2.01. Figures 1 and 2 show the median P02 and percentage of p02 values < 5 mmHg, before and after drug injection, for all the transplanted and spontaneous tumours used in this study.
To check on the validity of making repeated P02 measurements in tumours, measurements were made in transplanted tumours before and after injection with saline. The pretreatment median P02 values ranged from 2 to 8 mmHg (mean= 5 mmHg) and the percentage of P02 values < 5 mmHg ranged from 8% to 94% (mean = 55%). Following injection with saline the p02 measurements were repeated and although there was some variability between the pre-and post-saline measurements, there were no consistent changes. Moreover, the post-injection results covered a similar range (median values went from 2 to 9 mmHg and the percentage < 5 mmHg from 19% to 99%) as the presaline measurements, and the average estimates of the median P02 values and percentage of P02 values < 5 mmHg were calculated to be 5 mmHg and 58% respectively, which were not significantly different from the average presaline values. The pretreatment p02 values measured in the transplanted tumours used for the hydralazine study were almost identical to those seen in the saline-treated transplanted tumours. However, when mice were injected with hydralazine every single transplanted tumour became less well oxygenated. Indeed, for all ten tumours the average of the median p02 values was decreased from 5 to 3 mmHg, while the percentage of p02 values < 5 mmHg increased from 45% to 87%, and these changes in both parameters were significant. Similar significant changes were also seen for mean p02 and the percentage of values < 10 mmHg, but not for the percentage < 2.5 mmHg (data not shown).
For the spontaneous tumours the prehydralazine treatment P02 values did appear to show a wider range, at least in terms of median P02, than the pretreatment values measured in transplanted tumours, however, the average results for all ten spontaneous tumours were not significantly different from the average pretreatment p02 estimates of the transplanted tumours. After hydralazine treatment, every spontaneous Table   I . tumour showed a decreased oxygenation status. For the median p02 the average value for all ten tumours decreased from 8 to 2 mmHg, while the percentage of P02 values < 5 mmHg increased from 60% to 94%, and again these changes were significant. The average estimates for the mean PO2 and the percentage of values < 2.5 and 10 mmHg also showed significant differences between the pre-and posthydralazine treatments (data not shown).
Discussion
It has been established that the Eppendorf oxygen electrode can directly measure the oxygenation status of both animal and human tumours (Kallinowski et al., 1990; Hoeckel et al., 1993; Horsman et al., 1995) . Using this electrode we have now demonstrated that a large single dose of hydralazine (5 mg kg-') can significantly decrease the level of oxygenation in a transplanted C3H mouse mammary carcinoma. These changes were identical to those we reported for hydralazine in small 200 mm3 C3H tumours and are consistent with our radiation studies in this tumour, which showed that for several hours after hydralazine injection tumour response to radiation was equivalent to that seen in tumours made fully radiobiologically hypoxic by clamping (Horsman et al., 1989; Fisker et al., 1991) , an effect that correlated with the drug's ability to decrease tumour blood flow. Studies with other transplanted tumour models have also shown that hydralazine can decrease tumour blood flow (Voorhees and Babbs, 1982; Chaplin and Acker, 1987; Bhujwalla et al., 1990; Kalmus et al., 1990; Lin & Song, 1990; Honess and Bleehen, 1992; Dewhirst et al., 1994) and oxygenation (Stratford et al., 1987; Lin and Song, 1990; Lemmon and Brown, 1991) . Our current study also investigated the effect of hydralazine on the oxygenation status of ten spontaneous murine tumours and in every case a reduction in tumour oxygenation was observed. These tumours arose in mice that had either been whole-body irradiated some 11 to 17 months earlier, or in animals which 19-25 months before had been implanted in the right rear foot with the C3H mammary carcinoma and the tumour then controlled by local irradiation. Histological examination and measurement of DNAindex clearly showed that these spontaneous tumours were not recurrences of the previously transplanted tumour. Moreover, although some of the tumours may have been induced by the previous radiation treatment, the time at which the spontaneous tumours appeared and the site of growth, suggests that the irradiation was probably not responsible for all the tumours. Two other studies have looked at the effect of hydralazine in primary or spontaneous tumours, both using 3MP-MRS to assess response. One found that 12/19 primary tumours did not respond to hydralazine (Field et al., 1991) , while the other showed that 10/12 spontaneous tumours failed to respond to the drug . Why there should be this apparent discrepancy between the P02 and 31P-MRS data is not clear. The study by Field et al. (1991) used radiation-or chemically induced primary tumours and there is evidence showing that murine tumours that can respond to hydralazine do not do so if grown in a previously irradiated site (Lemmon and Brown, 1991) . While this may help explain the lack of effect in some of the primary tumours in the Field study, and why a non-responding primary tumour did respond when transplanted, it probably does not explain the failure to see an effect in all the primary tumours, nor does it account for the lack of effect in the majority of truly spontaneous tumours in the study by Wood et al. (1992) . Our PO2 measurements also showed that for at least four out of ten of the spontaneous tumours the percentage of P02 values < 5 mmHg before hydralazine treatment were around 80% or above. Such tumours could be considered very hypoxic and, although they did respond to hydralazine, they were incapable of showing any large change. Although 3'P-MRS can be used to monitor changes in tumour metabolism with growth or after treatment (Rofstad et al., 1988; Adams et al., 1992) , its ability to actually measure the level of hypoxia in tumours is limited (Rofstad et al., 1988; Nordsmark et al., 1995) . It is, therefore, possible that the failure to see a response in spontaneous tumours with 3'P-MRS after hydralazine may have been because these tumours were relatively hypoxic and unable to respond. However, this again is unlikely to be the explanation for the lack of effect with so many tumours in the 3"P-MRS studies; even in our experiments some 60% of the spontaneous tumours could be considered reasonably well oxygenated. Nor does it explain why hydralazine-induced changes in metabolic activity can be detected with 3'P-MRS in transplanted tumours (Okunieff et al., 1988; Bhujwalla et al., 1990; Tozer et al., 1990; Bremner et al., 1991) . Clearly there is no easy explanation as to why our current study showed substantial effects of hydralazine in spontaneous tumours using measurements Of PO2 as the end point, and other studies using 3"P-MRS failed to find such effects.
Nevertheless, the important finding from our current study is that all the spontaneous tumours we studied responded to hydralazine and the average effect was identical to that seen in size-matched, transplanted murine tumours. Whether or not hydralazine can actually be used clinically to decrease blood flow in human tumours and thus enhance the antitumour activity of hypoxic cell cytotoxins is not clear. Limited clinical data has shown that hydralazine can decrease blood flow in a glioblastoma (Chaplin and Trotter, 1991 ) and a squamous cell carcinoma , but actually increased flow by 38% in lung tumours . That latter effect was seen with a drug dose that produced only an 8% decrease in mean arterial blood pressure (Rowell and Clark 1990) . Experimental murine studies have also reported hydralazine-induced increases in tumour blood flow of around 30% (Kalmus et al., 1990; Horsman et al., 1992) , but these occurred at low drug doses and, as in the human lung studies, were associated with a small decrease in mouse blood pressure of about 10%. Only when blood pressure was reduced by 15% or more did blood flow drop below control levels (Horsman et al., 1992) . It seems unlikely that such large decreases in blood pressure can be routinely achieved in humans, although decreases in excess of 20% were observed in the glioblastoma and squamous cell carcinoma studies (B Acker, written communication, January 1991) . What is needed are agents that can physiologically decrease tumour blood flow without substantially decreasing blood pressure. Our finding that transplanted and spontaneous tumours responded identically to hydralazine suggests that transplanted tumours grown in mice would be a good effective screen to identify such agents.
